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Mucus hypersecretion is a distinguished feature of chronic inﬂammatory airway diseases. Interestingly, in this condition thyroid
function is impaired with decreased level of triiodothyronine (T3), indicating potential link between low level of T3 and mucus
hypersecretion. But the underlying mechanisms are poorly understood. In this study we aimed to elucidate the eﬀect of T3 on
MUC5AC secretion in human bronchial epithelial HBE16 cells and further investigate how T3 regulates MUC5AC gene expression
at transcriptional level. By RT-PCR and ELISA we showed that T3 inhibited MUC5AC mRNA expression and protein secretion
in HBE16 cells. Furthermore, luciferase assay and site-directed mutagenesis analysis demonstrated that T3 repressed MUC5AC
expression at transcriptional level and the mechanism might partly lie in the speciﬁc inhibition of Sp1 binding to the promoter.
Our results suggest that decreased T3 level leads to the release of repression of MUC5AC expression and thus contributes to mucus
hypersecretion.
1.Introduction
Mucus hypersecretion is a notable aspect of a variety of
chronic inﬂammation diseases including asthma, chronic
bronchitis, bronchiectasis, and cystic ﬁbrosis [1, 2]. Excessive
production of mucus leads to airway mucus obstruction,
thus contributing to the morbidity and mortality in these
diseases [3]. As the major component of mucus secre-
tions, mucins consist of a family of high-molecular weight
glycoproteins synthesized by the mucosal epithelial cells
that line digestive and reproductive tracts, middle ear, and
trachea [4]. To date, 20 mucin genes (MUC for human and
Muc for other species) have been identiﬁed. Among them,
MUC2, MUC5AC, and MUC5B are crucially implicated
in the pathogenesis of respiratory diseases [5]. Under
normal condition, mucins protect the epithelial cells by
binding and trapping the inhaled bacteria and viruses for
mucociliary clearance. However, under diseased conditions
such as chronic obstructive pulmonary disease (COPD), the
mucociliaryclearancemechanismbecomesdefective,andthe
excessiveproductionofmucinwillleadtoairwayobstruction
[6].
Notably,COPDischaracterizedbychronicinﬂammation
notonlyinthepulmonarycompartment,butalsoinsystemic
circulation. Several factors such as hypoxemia, exacerba-
tion, drugs, and malnutrition may lead to endocrinological
changes in COPD. In particular, alterations in thyroid func-
tion tests are common in chronic systemic diseases including
chronic heart failure, chronic liver or hematologic diseases,
cancer, diabetes, connective tissue diseases, and COPD [7].
Frequently detected abnormality of thyroid function in
nonthyroidal illness (NTI) includes a decreased level of
total triiodothyronine (TT3) as well as free triiodothyronine
(fT3).Interestingly,indiseasedconditionssuchasCOPDitis
frequently observed that thyroid function is impaired with a
decreased level of triiodothyronine (T3), indicating potential2 Journal of Biomedicine and Biotechnology
link between low T3 level and mucus hypersecretion. But the
underlying mechanisms are poorly understood.
Here we aim to address the eﬀe c to fT 3o nM U C 5 A C
secretion using the human bronchial epithelial cells HBE16
as a model. By luciferase assay we found that T3 repressed
MUC5AC expression, and we further characterized the
potential transcription factors and the corresponding bind-
ing sites in MUC5AC promoter involved in this regulation.
2.MaterialsandMethods
2.1. Reagents. The human bronchial epithelial cells HBE16
(a generous gift from Department of Pathology, Chongqing
Medical University) were cultured in RPMI-1640 (supple-
mented with 10% FBS, 100U/mL penicillin, and 100μg/mL
streptomycin) at 37◦C in a humidiﬁed atmosphere con-
taining 95% air and 5% CO2. The cells were seeded at
a ﬁnal concentration of 1 × 105 cells/mL in serum-free
medium and then treated with 5nM all-trans-retinoic acid
(RA) to maintain the basic level of MUC5AC expression.
In experimental group, additional T3 was added to the
culture medium to ﬁnal concentration of 0.1, 1, and 10nM,
respectively. After 24h, the cells and conditioned media were
collected to determine MUC5AC level.
2.2.RT-PCR. TotalRNAwasisolatedfromHBE16cellsusing
Trizol reagent (Roche) according to the manufacturer’s
instructions, and 1μg of total RNA was used for reverse
transcription in a 20μL ﬁnal volume with AMV Reverse
Transcriptase (Promega) according to the manufacturer’s
protocol. PCR was then performed on 1μL of cDNA using
following primers: MUC5AC 5 -TCAACGGAGACTGCG-
AGTACAC-3  and 5 -CTTGATGGCCTTGGAGCA-3 ,a m -
plicon 130bp; GAPDH 5 -ACCACAGTCCATGCCATCAC-
3  and 5 -TCCACCCTGTTGCTGTA-3 , amplicon 491bp.
PCR products were identiﬁed by 2% agarose gel elec-
trophoresis, and the relative level of MUC5AC mRNA was
analyzed based on the ratio to GAPDH.
2.3. MUC5AC ELISA. MUC5AC in the conditioned media
was measured by ELISA. 50μL of the media was incubated
with bicarbonate-carbonate buﬀer (50μL) at 40◦Ci na
96-well plate until dry. Plates were washed three times
with PBS and blocked with 2% BSA, fraction V (Sigma)
for 1h at room temperature. Plates were then washed
three times with PBS and incubated with 50μL/well of
mouse monoclonal MUC5AC antibody (Neomarkers, CA)
at 1:100 dilution in PBST (PBS containing 0.05% Tween
20). After 1h, plates were washed three times with PBS
and incubated with 100μL/well of HRP-goat anti-mouse lgG
conjugate(Roche)at1:10,000dilution.After1h,plateswere
washed three times with PBS. Color reaction was developed
with horseradish peroxidase solution (Kirkegaard & Perry
Laboratories) and stopped with 1M H2SO4. Absorbance
was read at 450nm. The results were expressed as ratio of
MUC5AC to standard product.
2.4. Construction of MUC5AC Promoter Plasmids. Diﬀer-
ent MUC5AC promoter regions were PCR-ampliﬁed from
genomic DNA of HBE16 cell using the following primers:
−1300/+48 5 -GTCGGTACCAATGGAGAAGTAGGCAA-
TCATA-3  and 5 -GTACTCGAGCAACACTCATTGTG-
TGGACG-3 ;−689/+48 5 -AGTGGTACCTGAGGGAC-
GCCTTGGCTCACT-3  and5 -GTACTCGAGCAACACTC-
ATTGTGTGGACG-3 ; −324/+48 5 -ACAGGTACCCT-
TAAGGCTGTTCTGACCACT-3  and5 -GTACTCGAGCA-
ACACTCATTGTGTGGACG-3 ; −64/+48 5 -ACAGGTAC-
CCGTGAAGCACGGGGCTGGA-3  and 5 -GTACTCGA-
GCAACACTCATTGTGTGGACG-3 . The PCR products
were subcloned into the pGL3-basic vector using KpnI/XhoI
sites to construct pGL3-MUC5AC-promoter plasmids and
conﬁrmed by sequencing.
2.4.1. Construction of Sp1 and NF-κB Expression Plasmids.
The coding sequences for human Sp1 and NF-κBw e r e
PCR-ampliﬁed from human full-length cDNA using the
following primers: Sp1 5 -TTCTGCCCACCCACGTGAAG-
CA-3  and 5 -CGGGGCCTGTGGTTCCCCCT-3 ;N F - κB
5 -AGGACCCCTGCAGGCCAG-3  and 5 -GGCCACATA-
CCCCACCCTAGAC-3 .The PCR products were subcloned
into pCMV3.0b vector using Kpn I/XhoI sites to construct
Sp1 and NF-κB expression plasmids, and then conﬁrmed by
sequencing.
2.5. Cell Transfection and Luciferase Assay. HBE16 cells were
seeded in 24-well plate and cotransfected with MUC5AC
promoterplasmidsandpRLSV40(internalcontrol)usingthe
Lipofect AMINE Plus reagent (Invitrogen, USA) following
the manufacturer’s protocol. T3 was added to a ﬁnal
concentration of 1nM 24h after transfection and incubated
for another 24h. Then cell lysate was collected, and ﬁreﬂy
and renilla luciferase activities were measured with a TD-
20/20 luminometer (USA). In other cases, HBE16 cells
were cotransfected with three plasmids (MUC5AC promoter
plasmids, transcriptional factor expression plasmids, and
pRL-SV40) and cocultured with T3 for 48h. Then cells were
lyzedandassayedforluciferaseactivity.Eachexperimentwas
performed in triplicate and repeated at least four times.
2.6. Site-Directed Mutagenesis of −324/+48 Region of MUC-
5AC Promoter. Site-directed mutagenesis of potential SP-1
binding site within MUC5AC −324/+48 promoter region
was performed using super high-ﬁdelity DNA polymerase
primer STARTM (Takara) with pGL3-MUC5AC −324/
+48 plasmid as template and the following primers:
5 -TTCTGCCCACCCACGTGAAGCA-3  and 5 -CGGGGC-
CTGTGGTTCCCCCT-3 .
2.7. Statistical Analysis. A l ld a t aw e r ee x p r e s s e da sm e a n s ±
SE. Data were analyzed by ANOVA and Dunnett’s t test using
SPSS10.0 software. P<0.05 was considered as signiﬁcant
diﬀerence and P<0.01 as highly signiﬁcant diﬀerence.
3. Results
3.1. T3 Inhibits MUC5AC mRNA Expression and Protein
S e c r e t i o ni nH B E 1 6C e l l s .RT-PCR and ELISA analysis
demonstratedthatT3inhibitedMUC5ACmRNAexpressionJournal of Biomedicine and Biotechnology 3
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Figure 1: T3 inhibits MUC5AC mRNA expression and protein secretion in HBE16 cells. (a) MUC5AC mRNA level was determined by
RT-PCR. (b) Secreted MUC5AC protein level was determined by ELISA.
∗P < 0.05 versus control group; #P>0.05 versus 10nM group.
0
2
4
6
8
10
12
14
16
18
R
L
U
Control
Experimental
−1330/ +48−689/ +48 −324/ +48 −64/ +48 pGL3-basic
∗ ∗ ∗
∗∗
##
# #
#
Figure 2: T3 inhibits the transcription of MUC5AC in HBE16 cells.
TheluciferaseactivitywasdeterminedasdescribedinMaterialsand
Methods. Control group: diﬀerent MUC5AC promoter plasmids
in the absence of T3; experimental group: diﬀerent MUC5AC
promoter plasmids in the presence of T3.
∗P < 0.01 versus pGL3-
basic control group;
∗∗P > 0.05 versus pGL3-basic control group;
#P>0.05 versus the same promoter control group; ##P< 0.01
versus the same promoter control group.
and protein secretion in HBE16 cells at the concentration
of 1 and 10nM (Figure 1). However, the inhibitory eﬀects
were not in a dose-dependent manner because no statistical
diﬀerence was found between 1nM group and 10nM
group. Taken together, these results suggest that T3 inhibits
MUC5AC expression.
3.2. T3 Regulates the Transcription of MUC5AC in HBE16
Cells. To explore whether T3 regulates MUC5AC expres-
sion at transcriptional level, diﬀerent regions of MUC5AC
promoter were characterized. As shown in Figure 2, the
luciferase activity was signiﬁcantly upregulated in HEB16
cells transfected with MUC5AC promoter constructs con-
taining fragment −1,330/+48, −689/+48, −324/+48 (P<
0.01) but not −64/+48 (P>0.05) as compared with pGL3-
basic vector control group, suggesting that −324/+48 com-
prises the eﬀective region for transcriptional regulation of
MUC5AC. Notably T3 showed inhibitory eﬀect on luciferase
activity only with MUC5AC promoter construct containing
fragment −324/+48, thus indicating that T3 indeed regulates
MUC5AC expression at transcriptional level.
3.3. T3 Selectively Antagonizes Sp1 but Not NF-κB-Dependent
TranscriptionofMUC5ACinHBE16Cells. Tofurtherexplore
the potential mechanism involved in the downregulation of
MUC5AC expression by T3, we assumed that T3 may inhibit
the combination of transciption factors with MUC5AC
promoter. To test this we made Sp1 and NK-κB expression
plasmids and cotransfect them with MUC5AC promoter
plasmids into HEB16 cells. Luciferase assay demonstrated
that Sp1 upregulated the luciferase activity only in com-
bination with −324/+48 region of MUC5AC promoter,
and T3 could signiﬁcantly inhibit Sp1-stimulated luciferase
activity (Figure 3(a)). These results suggest that Sp1 binds to
−324/+48 region of MUC5AC promoter to drive MUC5AC
transcription and T3 may inhibit the binding of Sp1 to
this region. To conﬁrm that the inhibitory eﬀect of T3 we
observed is not artiﬁcial we also tested NF-κB and found that
similar to Sp1, NF-κB upregulated the luciferase activity only
in combination with −324/+48 region of MUC5AC pro-
moter, suggesting that NF-κB also binds to −324/+48 region
of MUC5AC promoter to drive MUC5AC transcription.
However, T3 could not inhibit NF-κB-stimulated luciferase
activity (Figure 3(b)). To provide further evidence that T3
speciﬁcallyinhibits thebinding ofSp1to −324/+48regionof
MUC5AC promoter, we employed site-directed mutagenesis
to disrupt the potential Sp1 combined site within this region
and performed luciferase assay. The results demonstrated
that T3 failed to inhibit Sp1-stimulated luciferase activity in
the presence of mutant MUC5AC promoter (Figure 3(c)).
TheputativeSp1bindingsitewaslocatedat −80bpregionof
MUC5AC promoter. Taken together, these data demonstrate
thatT3selectivelyantagonizesSp1butnotNF-κB-dependent
transcription of MUC5AC, indicating that T3 speciﬁcally
inhibits the binding of Sp1 to MUC5AC promoter.
4. Discussion
T3 has been demonstrated to repress MUC5AC expression
and reduce secreted mucus in normal human tracheo-
bronchial epithelial NHTBE cells [8]. Additional studies4 Journal of Biomedicine and Biotechnology
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Figure 3: T3 selectively antagonizes Sp1 but not NF-κB-dependent transcription of MUC5AC in HBE16 cells. (a) After the cells were
cotransfected with Sp1 expression plasmid, the luciferase activity was determined as described in Materials and Methods. Blank: diﬀerent
MUC5AC promoter plasmids only; control: diﬀerent MUC5AC promoter plasmids plus Sp1 expression plasmid in the absence of T3;
experimental: diﬀerent MUC5AC promoter plasmids plus Sp1 expression plasmid in the presence of T3.
∗P > 0.05 versus blank;
∗∗P < 0.01 versus blank; #P> 0.05 versus control; ##P< 0.01 versus control. (b) After the cells were cotransfected with NF-κB expression
plasmid, the luciferase activity was determined as described in Materials and Methods. Blank: diﬀerent MUC5AC promoter plasmids only;
control: diﬀerent MUC5AC promoter plasmids plus NF-κB expression plasmid in the absence of T3; experimental: diﬀerent MUC5AC
promoter plasmids plus NF-κB expression plasmid in the presence of T3.
∗P > 0.05 versus blank;
∗∗P< 0.01 versus blank; #P> 0.05
versus control. (c) After the cells were cotransfected with Sp1 expression plasmid and MUC −324/+48 promoter plasmid or its mutation
form (mut), the luciferase activity was determined as described in Materials and Methods. Control: in the absence of T3; experimental: in
the presence of T3. ∗P< 0.01 versus −324/+48 control group; #P> 0.05 versus −324/+48 mut control group.
showed that T3 inhibits MUC5AC expression by decreasing
retinoidreceptorlevelsinhumanbronchialepithelialcells[9,
10]. Nevertheless, few studies have addressed the eﬀect of T3
onmucinexpression inthe contextofmucushypersecretion.
Therefore in this study we employed human bronchial
epithelial HBE16 cells as the model to investigate the eﬀectof
T3 on MUC5AC expression and the underlying mechanism.
Airway epithelial cells cultured under RA-deﬁcient con-
dition undergo squamous diﬀerentiation, and RA treatment
resulted in the restoration of the mucous phenotype and
mucus hypersecretion [11]. In our study, 5nM all-trans-
RA was used to maintain the basic expression of MUC5AC.
As the ﬁrst step to examine the inﬂuence of T3 on mucin
expression,weconductedT3concentrationresponsestudies.
The results showed that as few as 1nM T3 signiﬁcantly sup-
pressed MUC5AC mRNA and protein expression (Figure 1).
The physiological concentration of T3 has been deﬁned as
10nM, 0.1–2.5nM, or 1–10nM in previous reports, but
1nM is generally accepted as a physiological concentration
of T3 [12]. In this study we used T3 at 10nM at maximum
but mainly used T3 at 1nM, suggesting that our results are
in a physiological setting.
The biological eﬀects of T3 are mediated via retinoic
acid receptors (RARs), retinoid X receptors (RXRs), and
thyroid receptors (TRs), and both RARs and TRs require
heterodimerization with RXRs for optimal transcriptional
activity [13]. Although TR-RXR and RAR-RXR recognize
the same core sequence of direct repeats (i.e., AGGTCA) in
the promoter regions of target genes, they exhibit binding
speciﬁcity as determined by the nucleotides between the
direct repeats, and TR has been shown to activate or repress
transcription in either a ligand-dependent or a ligand-
independent manner, depending on the target genes [14].
For example, Tomic et al. reported that T3 suppressed
keratin expression in epidermal keratinocytes by binding to
negative response elements (nTRE) in the promoter regionJournal of Biomedicine and Biotechnology 5
[15]. Interestingly, Moon et al. reported that RA upregulated
and T3 downregulated MUC expression in cultured human
middle ear epithelial cells [16]. Unfortunately, few studies
have followed up to address the functional interaction
between RA and T3 in the regulation of MUC expression.
To explore whether T3 suppresses MUC5AC expres-
sion in HBE16 by binding to nTRE in the promoter
region of MUC5AC, we characterized MUC5AC promoter
by luciferase assay and found that MUC5AC promoter
activity region lies in the region of −1130 to −64, since
only promoter plasmid containing −64/+48 failed to show
transcription activity (Figure 2).
To further examine whether T3 represses MUC5AC
expression via modulating its promoter activity, we added
T3 to HBE16 cells transfected with MUC5AC promoter plas-
mids. The results showed that T3 had inhibitory eﬀect only
incellstransfectedwithplasmidcontaining −324/+48region
(Figure 2). Interestingly, this region contains one proximal
area of core start-CACCC, one binding site for NF-κB, and
three binding sites for Sp1, and point mutation of CACCC
had minor impact on the promoter activity of MUC5AC
as reported previously [17]. Thus we hypothesized that NF-
κB and/or Sp1 might be involved in T3-mediated repression
of MUC5AC expression. Our results demonstrate that both
NF-κBandSp1stimulateMUC5ACtranscriptionbybinding
the −324/+48 region, but only Sp1-stimulated transcription
can be inhibited by T3. In addition, we disrupted the
potential Sp1 combined site within the −324/+48 region by
site-directed mutagenesis and observed that T3 was unable
to inhibit Sp1-stimulated transcription activity under this
condition (Figure 3(c)). Gray et al. reported that the −1250
to −1200 region of MUC5AC promoter was crucial for T3-
mediated suppression of MUC5AC transcription [9]. The
diﬀerent mechanisms by which T3 mediates the suppression
of MUC5AC expression may explain why the promoter
region we identiﬁed is diﬀe r e n tf r o mt h a tb yG r a ye ta l .
Their results suggest that T3 may interact with RAR and
TR to modulate the −1250 to −1200 region of MUC5AC
promoter, while our data indicate that T3 regulate Sp-1
binding in −324/+48 region to repress MUC5AC transcrip-
tion. Signiﬁcantly, our results that T3 inhibits MUC5AC
expression through inﬂuencing the binding of Sp1 but not
TR to MUC5AC promoter are consistent with the emerging
conceptthatadirectbinding ofTRtoDNAisdispensablefor
T3-dependent gene suppression [18, 19].
5. Conclusion
OurresultssuggestthatdecreasedT3levelleadstotherelease
ofrepressionofMUC5ACexpressionandthuscontributesto
mucus hypersecretion. Modulation of T3 level may provide a
novel therapeutic approach for chronic inﬂammatory airway
diseases associated with mucus hypersecretion.
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